ERISA Preemption and Pharmacy Liens: When Federal Law Overrides State Protections

James Wong — Founder & Pharmacist, LienScripts | March 26, 2026 | 7 min read

ERISA preemption under 29 USC 1144 displaces state-law lien protections for self-funded employer health plans, but pharmacy liens occupy a separate legal channel that federal preemption does not reach. PI attorneys must understand this distinction to protect client recoveries at settlement.

ERISA preemption is the federal doctrine that displaces state insurance regulations when an employer-sponsored health plan is self-funded, and it fundamentally changes how subrogation and lien priority work in personal injury settlements. Pharmacy liens, however, arise from a separate contractual arrangement between the patient, the attorney, and the lien provider — not from the health plan — and ERISA preemption does not reach them.

• ERISA preemption under 29 USC 1144 overrides state-law protections like the made-whole doctrine for self-funded plans
• Pharmacy liens are contractual arrangements independent of the health plan and fall outside ERISA's preemptive scope
• Self-funded ERISA plans can assert full subrogation on benefits they paid, but cannot claim subrogation on lien-dispensed medications
• Understanding the boundary between ERISA-governed claims and pharmacy lien claims is essential for settlement allocation
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report that documents medication costs separate from plan-paid expenses

How ERISA Preemption Works in Personal Injury Cases

The Employee Retirement Income Security Act of 1974 (ERISA) governs employer-sponsored benefit plans. Section 514(a), codified at 29 U.S.C. § 1144(a), provides that ERISA "shall supersede any and all State laws insofar as they may now or hereafter relate to any employee benefit plan." For PI attorneys, this means that state-law doctrines protecting plaintiffs from aggressive subrogation — the made-whole doctrine, the common fund doctrine as applied under state law, and anti-subrogation statutes — do not apply to self-funded ERISA plans.

The Supreme Court confirmed this framework in FMC Corp. v. Holliday, 498 U.S. 52 (1990), holding that ERISA preempts Pennsylvania's anti-subrogation statute as applied to a self-funded plan. The practical consequence: when your client has a self-funded employer plan, the plan can enforce its subrogation terms as written in the Summary Plan Description (SPD), without any state-law reduction.

[!KEY] ERISA preemption applies only to "employee benefit plans" as defined by the statute. A pharmacy lien is not an employee benefit plan — it is a private contractual arrangement. This structural distinction is the foundation of the argument that pharmacy liens survive alongside ERISA subrogation claims.

The Critical Distinction: Plan Benefits vs. Pharmacy Lien Costs

ERISA plans assert subrogation over benefits the plan paid. The plan's right is limited to recovering "amounts paid or incurred" on behalf of the beneficiary. When medications are dispensed through a pharmacy lien arrangement — where the lien provider advances the cost and the patient agrees to repay from settlement proceeds — the ERISA plan has not paid for those medications.

According to James Wong, PharmD, founder of LienScripts, "The entire point of enrolling a patient in a pharmacy lien at intake is to create a clean separation between plan-paid medical costs and lien-funded prescription costs. When settlement negotiations begin, the ERISA plan's subrogation demand should include only costs it actually paid — not medications dispensed under a separate lien arrangement."

This separation is not merely theoretical. TPAs administering self-funded plans routinely issue subrogation demands that sweep broadly, sometimes including estimated pharmacy costs the plan never actually covered. PI attorneys must request itemized EOBs and confirm what the plan genuinely expended before negotiating any figure.

When ERISA Preemption Does Not Reach Pharmacy Liens

Federal courts have consistently held that ERISA preempts state laws that "relate to" employee benefit plans, interpreting that phrase broadly. However, a pharmacy lien does not "relate to" an ERISA plan in any legally cognizable way:

No connection to plan administration. The lien is established between the patient, the attorney, and the pharmacy lien provider. The employer plan is not a party, does not administer the lien, and has no contractual rights or obligations under it.

No impact on plan terms. The existence of a pharmacy lien does not alter the ERISA plan's coverage terms, benefit levels, or subrogation provisions. The plan continues to operate exactly as its SPD provides.

No regulatory interference. State lien laws that authorize pharmacy liens do not regulate employer benefit plans — they regulate the relationship between healthcare providers and patients in the tort recovery context.

[!TIP] At case intake, confirm whether your client's health insurance is through a self-funded employer plan by reviewing the SPD. If it is, enroll the client in a pharmacy lien immediately. This prevents ERISA subrogation exposure on medication costs entirely.

Settlement Allocation: Separating ERISA Claims from Pharmacy Liens

At settlement, the distribution waterfall must account for both the ERISA plan's subrogation claim and the pharmacy lien — but they are independent obligations with different legal foundations.

ERISA subrogation. The plan's recovery right is governed by federal law and the plan's SPD. After US Airways v. McCutchen, 569 U.S. 88 (2013), the plan's recovery may be reduced by the common fund doctrine (requiring pro-rata contribution to attorney fees) if the SPD is silent on attorney fee allocation.

Pharmacy lien. The lien is governed by state contract law and the lien agreement signed at intake. It is satisfied from the client's net recovery after attorney fees and costs. The ERISA plan has no priority claim over funds earmarked for the pharmacy lien because the plan never paid those costs.

The LienScripts platform provides a complete accounting of all lien-dispensed medications, including the MERIT (Medication Evaluation & Rationale for Injury Treatment) report documenting clinical necessity and treatment timelines. This documentation supports the argument that pharmacy costs are categorically separate from plan-paid expenses.

Practical Steps for PI Attorneys

1. Identify ERISA status at intake. Request the SPD and confirm whether the plan is self-funded or fully insured. Self-funded plans trigger ERISA preemption analysis.

2. Enroll in pharmacy lien before the plan pays for medications. If the plan has not yet processed pharmacy claims, enrolling in a lien ensures those costs never enter the plan's system.

3. Document the separation. Maintain records showing that lien-dispensed medications were never billed to the ERISA plan. The MERIT report from LienScripts provides this documentation automatically.

4. Challenge overbroad subrogation demands. When the TPA's demand includes pharmacy costs the plan did not pay, respond with itemized evidence showing those medications were lien-funded.

5. Apply McCutchen to reduce plan recovery. If the SPD lacks an express attorney fee provision, assert the common fund doctrine to reduce the plan's net subrogation recovery.

[!KEY] ERISA preemption is powerful but has defined boundaries. It preempts state law as applied to employee benefit plans — it does not grant plans the right to claim subrogation over costs they never incurred. Pharmacy liens exploit this boundary by keeping medication costs entirely outside the plan's payment system.

Related Resources

• ERISA Self-Funded Plans and Pharmacy Liens: What PI Attorneys Must Know
• Pharmacy Lien vs. ERISA Health Plan: What PI Attorneys Need to Know
• ERISA Made-Whole Doctrine and Pharmacy Liens
• ERISA Self-Funded Plan Defense for Pharmacy Liens